Clinical trials: Autoimmunity, Inflammation
Rheumatoid Arthritis (RA)
Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
Prospective, post-marketing, multi-center, open-label study to explore if the initiation of adalimumab could influence grey-scale (GS) and power Doppler (PD) ultrasonographic (US) score using 36-joint plus 4-tendon scoring…
- Trial name
- NCT02786563
- Where
- 4 sites in China
- Sponsor
- AbbVie
Rheumatoid Arthritis
The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis
Patients will be assigned to receive either Depo Medrol or Acthar treatment. A synovial biopsy, blood draws, synovial fluid aspiration, and physician assessments will be performed before and after initiating treatment.
- Trial name
- NCT03511625
- Testing
- Acthar Injectable Product, Depo medrol
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Attune Health Research, Inc.
Relapsing Forms of Multiple Sclerosis
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study.
- Trial name
- FUSION (NCT05798520)
- Testing
- BIIB091, DRF
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 127 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Cellular microRNA Signatures in Multiple Sclerosis
A limited number of studies on microRNA expression variation in immune cells have been reported in relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- SEP-MIR (NCT05290688)
- Testing
- 50 ml blodd sampling
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut Pasteur
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
IgA Nephropathy
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
Efficacy and safety of LNP023 in IgAN patients
- Trial name
- NCT03373461
- Testing
- LNP023
- Where
- 56 sites in Argentina, Australia and 23 more
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Inflammation, Rheumatoid Arthritis
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to placebo when administered as weekly…
- Trial name
- NCT01636843
- Testing
- NNC0109-0012
- Where
- 139 sites in United States, Argentina and 12 more
- Volunteers
- 298 people
- Sponsor
- Novo Nordisk A/S
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Autistic Disorder
Proteomic Biomarker Tests in Blood Samples from Children with Autism Spectrum Disorder (ASD)
Behavioral testing is the gold standard for diagnosing autism spectrum disorder (ASD). These tests, including ADOS and ADI-R, are subjective, require trained staff to administer, are time-consuming, and can only be administered…
- Trial name
- NCT02168868
- Testing
- Blood draw, Stool Sample Collection, Urine Sample Collection
- Where
- Israel
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Benjamin Gesundheit
Rheumatoid Arthritis
An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World Practice
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many patients remain sub-optimally…
- Trial name
- UPDATE (NCT05327920)
- Where
- 8 sites in Hungary
- Volunteers
- 93 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Psoriatic Arthritis
Research Study on the Immunosuppressive Effects of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases
Rheumatic diseases regroup a variety of disorders affecting the locomotor system including joints, muscles, connective tissues and soft tissues around the joints and bones.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
- Trial name
- NCT03454932
- Testing
- Blood sampling
- Volunteers
- 30 people
- Sponsor
- Bone Therapeutics S.A
Rheumatoid Arthritis
Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)
The purpose of this study is to evaluate the safety of an additional 28 weeks of treatment with pegsunercept for subjects who have completed treatment in a previous double-blind study (20000201 or 20000198).
- Trial name
- NCT00111423
- Testing
- Pegsunercept (PEG sTNF-RI)
- Volunteers
- 216 people
- Sponsor
- Amgen
Lupus Nephritis
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
- Trial name
- SIRIUS-LN (NCT05126277)
- Testing
- ianalumab s.c. q4w, ianalumab s.c. q12w
- Where
- 145 sites in United States, Argentina and 25 more
- Volunteers
- 452 people
- Sponsor
- Novartis Pharmaceuticals
Endometriosis
Open Label Immunotherapy of Endometriosis
Endometriosis is a chronic gynecological disease characterized by sustained painful symptoms that are responsible for a decline in the quality of life of sufferers.
- Trial name
- NCT03340324
- Testing
- V-Endo
- Where
- Mongolia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Immunitor LLC
Primary Progressive Multiple Sclerosis, Primary Progressive MS
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
- Trial name
- NCT07840326
- Testing
- SUN-627
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sundance Biosciences, Inc.
Rheumatoid Arthritis
Safety of Splenic Stimulation for RA
This study will evaluate the safety and tolerability of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories.
- Trial name
- NCT04955899
- Testing
- Active Stimulation
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Galvani Bioelectronics
Autoimmunity, Inflammation
Secukinumab Open Label Roll-over Extension Protocol
The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are…
- Trial name
- NCT04638647
- Testing
- Secukinumab s.c. injection
- Where
- 171 sites in United States, Brazil and 18 more
- Volunteers
- 1,000 people
- Sponsor
- Novartis Pharmaceuticals
Inflammation, Systemic Lupus Erythematosus (SLE)
An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)
This trial is conducted in North America. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetic and signs of bioactivity of increasing single doses of AGS-009 in patients with systemic lupus…
- Trial name
- NCT00960362
- Testing
- AGS-009
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Argos Therapeutics
Arthritis, Rheumatoid
A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques
This is an adaptive Positron Emission Tomography/ Computed Tomography (PET/CT) and Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) open-label study design for the investigation of inflammation in adult rheumatoid…
- Trial name
- NCT02350426
- Testing
- Gadobutrol, 18F-FDG, 18F-GE-180
- Where
- 2 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Inflammation, Rheumatoid Arthritis
A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
This trial is conducted in Europe. The aim of the trial is to investigate the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biopsies in subjects with rheumatoid arthritis (RA) and an inadequate response to…
- Trial name
- NCT02097264
- Testing
- NNC0109-0012, Adalimumab
- Sponsor
- Novo Nordisk A/S